

특발성 확장성 심근병증에서 좌심실 수축기 기능 향상에 영향을 주는 인자에 대한 연구

김진구 · 박정의 · 남궁준 · 이상철 · 권현철 · 박승우
김준수 · 전은석 · 김덕경 · 이상훈 · 홍경표 · 서정돈

Factors Influencing the Improvement of Left Ventricular Systolic Function in Patients with Idiopathic Dilated Cardiomyopathy

Jin Ku Kim, MD, Jeong Euy Park, MD, June Namgung, MD, Sang-Chol Lee, MD, Hyeon-Cheol Gwon, MD, Seung Woo Park, MD, June Soo Kim, MD, Eun-Seok Jeon, MD, Duk-Kyung Kim, MD, Sang Hoon Lee, MD, Kyung Pyo Hong, MD and Jung Don Seo, MD

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Cardiac & Vascular Center, Seoul, Korea

ABSTRACT

Background and Objectives : Idiopathic dilated cardiomyopathy (IDC) is a disease entity with no known specific curative measures. However, significant improvement in the left ventricular (LV) systolic function, during the management course for IDC, is frequently observed. In this study we tried to ascertain associated factors for the improvement of the LV function in patients with IDC. **Subjects and Methods** : Thirty-three patients, newly diagnosed as IDC between Jan. 1999 and Jan. 2001, on whom a 6-month follow-up echocardiography was performed, were included in the study. Improvement in the LV systolic function was defined as an increase in the LV ejection fraction greater than 10% from the baseline. The subjects were divided into two groups; the improved group (IG) and the unimproved group (UG). The clinical characteristics and management methods were evaluated, and compared between the two groups. **Results** : Seventeen patients (M/F : 15/2) were included in the IG, and 16 (M/F : 7/9) were included in the UG. There were no significant differences in the baseline LV systolic function (IG : $23.4 \pm 1.5\%$ vs. UG : $28.9 \pm 2.3\%$), age, NYHA functional class or resting heart rate on admission between the two groups. b-blocker therapy ($p = 0.002$), the absence of diabetes mellitus ($p = 0.046$) and male sex ($p = 0.007$), were all significantly associated with an improvement in the LV systolic function from the univariate analyses. With the multivariate analyses, only b-blocker therapy was significantly associated with an improvement in the LV systolic function. The 6-month event-free survival rate was significantly better in the IG compared with UG ($94 \pm 5\%$ vs. $63 \pm 13\%$, $p = 0.031$). **Conclusion** : b-blocker therapy exerts a considerable effects on the improvement in the LV systolic function of patients with IDC. (Korean Circulation J 2002;32(12):1064-1071)

KEY WORDS : Cardiomyopathy, congestive ; Adrenergic beta-antagonists ; Therapeutics ; Heart failure, congestive.

: 2002 7 10
: 2002 10 18
: 2002 10 22
: , 135 - 710 50
: (02) 3410 - 3416 · : (02) 3410 - 3417 · E - mail : jepark@smc.samsung.co.kr

서 론

가 , 0.04% , 8 oz 6
가 , 6
가 ,
가 ,
가 , 1980 3
30%, 5 60% 6
가
가 , 10%
(Improved group ; IG),
(Unimproved group ; UG)
(Modified Simpson's method)
2

자료 분석 방법

대상 및 방법

환자군

1999 1 2001 1
2001 7 6
가

58 mm ,
(ejection fraction) 40%
가

201

200 mmHg , 5

(mean SEM)
SPSS for windows(ver. 9.0) student
t - test (chi - square test)
p<0.05 가
가
event - free survival rate
Kaplan - Meier test , log -
rank test

결 과

임상적 특징

33 ,

17 (15), 16 (7) (deceleration time) 가 (Table 2).
 가
 (p=0.007), 가
 ,
 (p=0.046),
 가
 New York Heart Association(NYHA) functional class,
 가
 19.7 ± 1.0 , 17.4 ±
 1.5 (Table 1).

진단시 심초음파 지표

, 23.4 ± 1.5%,
 28.9 ± 2.3% 가
 ,

Table 1. Baseline characteristics of patients with idiopathic dilated cardiomyopathy in improved and unimproved group

	Improved group (n = 17)	Unimproved group (n = 16)	p
Sex (n, M/F)	15/2	7/9	0.007
Age (years)	51.0 ± 2.8	59.9 ± 4.0	NS
Hypertension (n)	5	8	NS
DM (n)	1	6	0.046
Hyperlipidemia (n)	1	3	NS
Smoking (n)	6	4	NS
Azotemia (n)	1	4	NS
PAOD (n)	2	0	NS
HR on admission (bpm)	95.6 ± 7.5	85.9 ± 4.1	NS
NYHA FC on admission (n)			NS
I	0	0	
II	6	4	
III	7	7	
IV	4	5	
Duration to therapy (month)	12.1 ± 3.1	13.6 ± 4.4	NS
Follow-up duration (month)	19.7 ± 1.0	17.4 ± 1.5	NS

All data including continuous variables are expressed as mean ± SEM. DM : diabetes mellitus, PAOD : peripheral arterial occlusive disease, HR : heart rate, NYHA FC : New York Heart Association functional class

치료 약물

,
 (p=0.002)(Table 3).
 Carvedilol ,
 , 가
 21.6 ± 2.3 mg(; 6.25 ± 37.5 mg/day),
 20.8 ± 4.2 mg(; 12.5 ± 37.5 mg/day)

Table 2. Comparison of echocardiographic parameters between improved and unimproved group on admission and follow-up over 6-month

	Improved group (n = 17)	Unimproved group (n = 16)	p
EF-pre (%)	23.4 ± 1.5	28.9 ± 2.3	NS
EF-post (%)	42.3 ± 2.6	27.8 ± 6.8	<0.001
LVIDd-pre (mm)	70.8 ± 1.4	66.4 ± 1.5	0.043
LVIDd-post (mm)	63.2 ± 1.6	67.0 ± 1.2	NS
LVIDs-pre (mm)	61.4 ± 1.7	55.8 ± 1.9	0.036
LVIDs-post (mm)	47.9 ± 2.1	55.4 ± 1.6	0.009
DT-pre	187.0 ± 24.2	240.0 ± 20.4	NS
DT-post	233.1 ± 17.0	267.8 ± 21.1	NS
LA-pre (mm)	50.1 ± 2.5	43.0 ± 2.0	0.034
LA-post (mm)	45.9 ± 2.0	41.1 ± 1.6	NS

All data expressed as mean ± SEM. "pre" implies data on admission and "post" on follow-up over 6-month. EF : ejection fraction, LVIDd : left ventricular end-diastolic dimension, LVIDs : left ventricular end-systolic dimension, LA : left atrium, DT : deceleration time

Table 3. Comparison of used drugs between improved and unimproved group

	Improved group (n = 17)	Unimproved group (n = 16)	p
ACEI	16	14	NS
-blocker	15	6	0.002
ACEI + -blocker	14	6	0.008
Digoxin	7	8	NS
Diuretics	17	16	NS
Spironolactone	6	5	NS

ACEI : angiotensin converting enzyme inhibitor

가 . 2 Metoprolol
50 mg 100 mg .

NYHA functional class IV 1 ,
(peripheral arterial occ-
lusive disease) 1 ,
NYHA functional class IV
가 5 , 가 3 ,
가 1
가 1

임상 사건

1 1 가
4 6 가 .

1 가 .
6 event - free survival rate
 $94 \pm 5\%$, $63 \pm 13\%$
(Fig. 1)
 $p = 0.031$).

주적 관찰시 변화




Fig. 1. Six-month event-free survival rate between improved group and unimproved group showed significant differences on Kaplan-Meier with log-rank test. Clinical events were defined as all cause mortality and hospitalization by aggrava-tion of heart failure.

$42.3 \pm 2.6\%$ ($p < 0.001$),
 $27.8 \pm 6.8\%$ 가 ,
 9.6 ± 1.5 .

(Table 2)(Fig. 2). NYHA functional class

class III, IV 가
65% 0% , 75%
44% ,
(Fig. 3)($p < 0.001$).




Fig. 2. In improved group, changes of echocardiographic parameters during follow-up showed significant improvement, but in unimproved group, there was no definite change.




Fig. 3. NYHA functional class was improved during follow-up in both groups. However, there was more significant improvement in improved group. NYHA : New York Heart association.

Table 4. Multivariate logistic regression analysis

	p	OR	95% Confidence interval
Sex	0.218	8.919	0.273 - 291.589
DM	0.271	53.352	0.045 - 6339.907
NYHA FC	0.170	10.4.5	0.366 - 295.745
HR	0.389	0.953	0.853 - 1.063
EF	0.662	0.921	0.638 - 1.331
LVIDd	0.188	2.187	0.683 - 7.004
LVIDs	0.184	0.463	0.149 - 1.44
-blocker	0.026	0.014	0.001 - 0.547

DM : diabetes mellitus, NYHA : New York Heart association functional classification, HR : heart rate, EF : ejection fraction, LVIDd : left ventricular end-diastolic dimension, LVIDs : left ventricular end-systolic dimension

좌심실 수축기 구혈을 향상에 영향을 미치는 인자

(univariate analysis)

, ($p=0.007$), ($p=0.046$),
($p=0.002$) ($p=$
 0.043), ($p=0.036$) .

NYHA functional class,

(p = 0.026 ; OR = 0.014 ; 95% CI : 0.001~0.547)가
가 (Table 4).

고찰

[illegible]

가 ,

(p = 0.026, OR = 0.014)가 가

방 법 :

1999 1 2001 1

2001 7 6

가

58 mm ,

40% ,

가

6

(Modified Simpson's method) , 10%

(Improved group) ,

(Unimproved group)

결 과 :

33 가 , 17

(15), 16 (7) ,

가 (p = 0.007),

(p = 0.046),

가

23.4 ±

1.5%, 28.9 ± 2.3% 가

(p = 0.002), 가

6 Event-free survival rate 94 ±

5% 63 ± 13% (p =

0.031). 6

42.3 ± 2.6%

가 (p < 0.001),

NYHA functional class

결 론 :

중심 단어 : ; - ; ;

2001

REFERENCES

- 1) Richardson P, McKenna W, Bristow M, Masich B, Mautner B, O'Connell JB, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P. *Report of the 1995 world health organization/international society and federation of cardiology (WHO/ISFC) task force on the definition and classification of cardiomyopathies. Circulation* 1996;93: 841-2.
- 2) World Health Organization/International Society and Federation Cardiology. *Reports of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J* 1980;44:672-3.
- 3) Dec GW, Fuster V. *Idiopathic dilated cardiomyopathy. N Engl J Med* 1994;331:1564-75.
- 4) Kasper EK, Agema WR, Hutchins GM, Deckers JW, Hare JM, Baughman KL. *The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol* 1994;23:586-90.
- 5) Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL. *The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol* 1981;47:525-31.
- 6) Felker GM, Hu W, Hare JM, Hruban RH, Baughman KL, Kasper EK. *The spectrum of dilated cardiomyopathy: the Johns Hopkins experience with 1,278 patients. Medicine* 1999;78:270-83.
- 7) Redfield MM, Gersh BJ, Bailey KR, Ballard DJ, Rodeheffer RJ. *Natural history of idiopathic dilated cardiomyopathy: effect of referral bias and secular trend. J Am Coll Cardiol* 1993;22:1921-6.
- 8) Azuma A, Matsuo A, Nakamura T, Kawasaki T, Yamamoto K, Hyogo M, Hirata A, Hirasaki S, Shima T, Sugihara H, Kunishige H, Kuribayashi T, Nakagawa M. *Improved survival of idiopathic dilated cardiomyopathy in the 1990s. Jpn Circ J* 1999;63:333-8.
- 9) Clements IP, Miller WL, Olsen LJ. *Resting heart rate and cardiac function in dilated cardiomyopathy. Int J Cardiol* 1999;72:27-37.
- 10) Kawai K, Takaoka H, Hata K, Yokota Y, Yokoyama M. *Prevalence, predictors, and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathy. Am J Cardiol* 1999;84: 671-6.

- 11) Cicoira M, Zanolla L, Latina L, Rossi A, Golia G, Brighetti G, Zardini P. *Frequency, prognosis and predictors of improvement of systolic left ventricular function in patients with classical clinical diagnosis of idiopathic dilated cardiomyopathy.* *Eur J Heart Fail* 2001;3:323-30.
- 12) Rihal CS, Nishimura RA, Hatle LK, Bailey KR, Tajik AJ. *Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy: relation to symptoms and prognosis.* *Circulation* 1994;90:2772-9.
- 13) Naqvi TZ, Goel RK, Forrester JS, Davidson RM, Siegel RJ. *Usefulness of left ventricular mass in predicting recovery of left ventricular systolic function in patients with symptomatic idiopathic dilated cardiomyopathy.* *Am J Cardiol* 2000;85:624-9.
- 14) Naqvi TZ, Goel RK, Forrester JS, Siegel RJ. *Myocardial contractile reserve on dobutamine echocardiography predicts late spontaneous improvement in cardiac function in patients with recent onset idiopathic dilated cardiomyopathy.* *J Am Coll Cardiol* 1999;34:1537-44.
- 15) Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. *Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy.* *Lancet* 1993;342:1441-6.
- 16) The RESOLVD Investigators. *Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study.* *Circulation* 2000;101:378-84.
- 17) Australia/New Zealand Heart Failure Research Collaborative Group. *Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease.* *Lancet* 1997;349:375-80.
- 18) Steimle AE, Stevenson LW, Fonarow GC, Hamilton MA, Moriguchi JD. *Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation.* *J Am Coll Cardiol* 1994;23:553-9.
- 19) Figulla HR, Rahlf G, Nieger M, Luig H, Kreuzer H. *Spontaneous hemodynamic improvement or stabilization and associated biopsy findings in patients with congestive cardiomyopathy.* *Circulation* 1985;71:1095-104.
- 20) Sugrue DD, Rodeheffer RJ, Codd MB, Ballard DJ, Fuster V, Gersh BJ. *The clinical course of idiopathic dilated cardiomyopathy: a population-based study.* *Ann Int Med* 1992;117:117-23.
- 21) Manolio TA, Baughman KL, Rodeheffer R, Pearson TA, Bristow JD, Michels W, Abelmann WH, Harlan WB. *Prevalence and etiology of idiopathic dilated cardiomyopathy.* *Am J Cardiol* 1992;69:1458-66.
- 22) Mann-Rouillard V, Fishbein MC, Naqvi TZ, DonMichael TA, Siegel RJ. *Frequency of echocardiographic improvement in left ventricular cavity size and contractility in idiopathic dilated cardiomyopathy.* *Am J Cardiol* 1999;83:131-3.
- 23) Douglas PS, Morrow R, Ioli A, Reichek N. *Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy.* *J Am Coll Cardiol* 1989;13:311-5.
- 24) Khanlou H, Paltoo B, Forbes W. *Echocardiographic parameters in reversible idiopathic dilated cardiomyopathy.* *Am J Med Sci* 2000;319:366-9.
- 25) Shen WF, Tribouilloy C, Rey JL, Baudhuin JJ, Boey S, Dufosse H, Lesbre JP. *Prognostic significance of Doppler-derived left ventricular diastolic filling variables in dilated cardiomyopathy.* *Am Heart J* 1992;124:1524-33.
- 26) Werner GS, Schaefer C, Dirks R, Figulla HR, Kreuzer H. *Doppler echocardiographic assessment of left ventricular filling in idiopathic dilated cardiomyopathy during a one-year follow-up: relation to the clinical course of disease.* *Am Heart J* 1993;126:1408-16.